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ABSTRACT
Objective: To investigate the effect of autoimmune thyroiditis (AIT) on risk of stroke and to assess
whether any increased risk (1) varied by AIT duration, and (2) was independent of classic cardio-
vascular risk factors.
Methods: This was a large historical cohort study using data from The Health Improvement
Network Database. Rates of first stroke during follow-up in thyroxine-treated patients with AIT
(n 5 34,907) were compared with those in matched individuals without AIT (n 5 149,632) using
random-effects Poisson regression models.
Results: There was strong evidence for a slightly increased risk of stroke in patients with AIT
(adjusted rate ratio 5 1.10, 95% confidence interval: 1.01–1.20). The observed increase was
partly independent of cardiovascular risk factors. Higher effect sizes were identified in the first
year after AIT diagnosis (rate ratio 5 1.33, 95% confidence interval: 1.14–1.56) but not in the
long-term, consistent with a residual effect of hypothyroidism.
Conclusion: Our results support the hypothesis of a slightly increased risk of stroke in patients
with AIT. The higher effect size found soon after AIT diagnosis suggests an increased cardiovas-
cular risk due to thyroid-hormone deficiency rather than a cumulative effect of autoimmune
pathology. Better screening and early treatment of patients with asymptomatic hypothyroid
AIT could help reduce excess risk of stroke in the first year after diagnosis. Neurology®
2014;82:1643–1652
GLOSSARY
AF 5 atrial fibrillation; AIT 5 autoimmune thyroiditis; BMI 5 body mass index; CHD 5 coronary heart disease; CHF 5 con-
gestive heart failure; CI 5 confidence interval; RR 5 rate ratio; THIN 5 The Health Improvement Network.
Autoimmune thyroiditis (AIT) is one of the most common autoimmune diseases in Western
countries.1,2 In iodine-deplete areas, such as the United Kingdom, AIT causes .90% of all
noniatrogenic cases of hypothyroidism, and the terms are often used interchangeably.3,4
Individuals with hypothyroidism/AIT have long been hypothesized to be at increased risk of
cardiovascular events, with a recent meta-analysis suggesting an increased risk of approximately
20% for coronary heart disease (CHD).5–14 Potential causal pathways between hypothyroidism
and CHD include hyperlipidemia, hypertension, diabetes, and obesity.3,15–21
Unlike CHD, there have been few epidemiologic studies of whether hypothyroidism
increases cerebrovascular disease risk. These have reported conflicting results and were mostly
small studies with methodologic limitations.7,21–26 Cerebrovascular risk factors (e.g., increased
carotid artery intima-media thickness and atrial fibrillation [AF]) have been linked to AIT or
hypothyroidism of unspecified cause, suggesting pathways from AIT to stroke independent of
general cardiovascular risk factors.23,27 Furthermore, autoimmune pathology in AIT might itself
affect cerebrovascular risk, as has been shown for other autoimmune diseases.16,28
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These uncertainties have led to calls for
large cohort studies to investigate the associa-
tion between AIT and cerebrovascular dis-
ease.21 The primary objective of our study
was to assess the effect of AIT on risk of stroke
and TIA using a large dataset derived from UK
primary care records. Secondary objectives
were to examine to what extent any effect of
AIT on cerebrovascular disease (1) was inde-
pendent of classic cardiovascular risk factors,
and (2) could be attributable to thyroid hor-
mone deficiency or autoimmune pathology.
METHODS Study design and study population. This was
a historical cohort study using data from The Health Improve-
ment Network (THIN) database. THIN is a population-based
database of electronic health records of approximately 6 million
patients from more than 300 general practices in the United
Kingdom.29 THIN has been validated for a wide range of medical
conditions, including stroke, and individuals contributing data to
THIN are representative of the UK population.30,31 Data available
include prescribed medications, medical diagnoses, lifestyle
conditions, demographic/personal information, and feedback from
specialist appointments and hospital admissions. The present study
population was a subset of a larger THIN study, in which patients
with an autoimmune disease enrolled in THIN between 1987 and
2007 had each been matched by age, sex, and general practice to up
to 6 individuals without any autoimmune disease.
Exposure and outcome. AIT was the exposure of interest;
unexposed individuals comprised patients without AIT (or any
other autoimmune disease) who had been matched on age, sex,
and general practice to the patients with AIT in the original THIN
dataset. The outcome of interest was first-ever stroke (including
ischemic and hemorrhagic) or TIA during follow-up. Exposure
and outcome were defined using prespecified Read code lists
(appendix e-1 on the Neurology® Web site at Neurology.org).
Study period. Start of follow-up for individuals with AIT and
their unexposed counterparts was the date of the first thyroxine
prescription in the patients with AIT (the index date). End of
follow-up was defined as the day of the outcome (stroke or
TIA) or end of follow-up in THIN (death, transfer out, or the
practice’s last data-collection date).
Eligibility criteria. Patients with AIT must have been first diag-
nosed with AIT during active follow-up in THIN and have been
prescribed thyroxine during follow-up. Individuals with other
causes for hypothyroidism (e.g., previous thyroidectomy) were
excluded from analyses (figure 1). Diagnoses for past or ongoing
conditions (including AIT) are sometimes recorded retrospectively
in the first few months after a patient registers with a practice.30 To
ensure that we enrolled incident cases, we excluded patients with
AIT who were diagnosed during their first year of follow-up in
THIN. All individuals (exposed and unexposed) who had a code
for stroke or TIA before start of follow-up, or who were younger
than 18 years, were not considered for inclusion. Also, because the
unexposed (non-AIT) individuals had no other autoimmune
disorders, individuals with AIT who had a preexisting or who
developed a second autoimmune disorder were also excluded.
Unexposed individuals had to be actively enrolled in THIN at
the index date of their matched individual with AIT; to ensure
that they were truly active, they had to have a consultation with
the practice in the 6 months before or in the year after the index
date of the patient with AIT.
Analysis. In the conceptual framework for this study (figure 2),
cofactors were categorized as follows: (1) a priori confounders
(sex, current age, general practice); (2) other potential confound-
ers (smoking, alcohol consumption, calendar year, time in study);
and (3) factors that could be either confounders or on the causal
pathway from AIT to stroke, depending on whether they occurred
before or after AIT diagnosis (figure 2B). Missing data for smoking,
alcohol, and body mass index (BMI) were treated using the missing
indicator method. An individually matched analysis is not needed
in matched cohort studies, but inclusion of the matched variables in
a multivariable analysis is advisable32; this also addressed any im-
balances between exposed and unexposed patients regarding these
variables after the application of exclusion criteria.
Statistical analyses were conducted using Stata 11 (StataCorp,
College Station, TX). Baseline characteristics were compared
using cross-tabulation, means or medians as appropriate, and x2
tests, 2-sided t tests, and Wilcoxon rank-sum tests.
Main analyses were performed using random-effects multi-
variable Poisson regression models allowing for clustering within
general practice. Four different models were built. The first
adjusted for sex and current age. In the second model, we assessed
potential confounding by smoking, alcohol consumption, calen-
dar year, and time in study, introducing these variables sequen-
tially into the model and retaining them if they changed the
effect estimate of AIT on stroke incidence appreciably. The third
model additionally assessed risk factors (hypertension, AF, hyper-
lipidemia, diabetes, CHD, congestive heart failure [CHF], and
BMI) that were present at the index date and could therefore also
confound the association between AIT and stroke. In the final
model, we examined time-updated values of these factors for in-
dividuals who developed these conditions during follow-up to
assess potential causal pathways between diagnosed AIT and
stroke. We applied this analysis strategy to 2 main outcomes, first
stroke, then stroke or TIA. In all models, standard errors were
examined for evidence of colinearity, and p values were obtained
using likelihood ratio tests.
We investigated effect modification by AIT duration as a proxy
for the effects of hypothyroidism (likely to be evident in the early
stages of disease, before adequate thyroxine replacement) vs the pos-
sible cumulative effect of autoimmunity (long-term increased risk,
likely to occur later during follow-up). We also investigated effect
modification by age (,60, 60–80,.80 years) and performed several
sensitivity analyses. First, analyses were repeated starting follow-up at
the date of first AIT code instead of first thyroxine script. Second,
cardiovascular conditions present among patients with AIT at diag-
nosis could be early mediating factors for stroke rather than a con-
founding variable; to assess their importance, we performed
subgroup analyses for individuals without a history of any cardiovas-
cular disease–related conditions at baseline.
Standard protocol approvals, registrations, and patient
consents. Ethics approval was obtained from the South-East
Multicentre Research Ethics Committee and from the London
School of Hygiene and Tropical Medicine Ethics Committee.
RESULTS In total, 184,539 eligible individuals from
287 general practices were included in this study, of
whom 34,907 had AIT (figure 2) and 149,632 had
no evidence of AIT. Individuals with AIT were
slightly older than individuals without AIT (median
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59.8 vs 57.0 years), were followed up for longer
(median 3.2 vs 3.0 years), and a slightly higher pro-
portion was female (81.5% vs 80.0%; table 1). Current
smoking and heavy drinking were less common among
those with AIT. For cardiovascular risk factors, indi-
viduals with AIT were more likely to have been diag-
nosed with hypertension, diabetes, hyperlipidemia,
CHD, or CHF at baseline (all p , 0.001). This pat-
tern remained after adjusting for the slight age and sex
imbalances (data not shown).
Individuals with AIT had a 13% increased rate of
stroke compared with individuals without AIT after
adjusting for current age and sex and allowing
for clustering in practice (model 1, table 2). The
increased risk was very similar (rate ratio [RR] 5
1.14, 95% confidence interval [CI]: 1.04–1.24,
p 5 0.003) after adjusting for alcohol and smoking
(model 2) and was not affected by the duration of
follow-up or calendar year. The RR decreased slightly
to 1.10 (95% CI: 1.01–1.20, model 3) after adjusting
additionally for cardiovascular risk factors present
at baseline (hypertension, hyperlipidemia, AF, and
BMI) and was not further changed by consideration
of existing diabetes, CHD, and CHF.
Individuals with AIT had an increased risk of
developing CHD, hyperlipidemia, CHF, and diabe-
tes during follow-up compared with unexposed indi-
viduals (table e-1), but not hypertension or AF. After
Figure 1 Flowchart of the selection process for patients with AIT
AID 5 autoimmune disease; AIT 5 autoimmune thyroiditis.
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adjusting for these potential mediating factors
between AIT and stroke, the RR for stroke was fur-
ther reduced to 1.06 (95% CI: 0.97–1.15, model 4).
Effect sizes were slightly higher for all models when the
outcome definition was expanded to both stroke and
TIA (table 2).
There was evidence that the effect of AIT on
stroke varied with duration of disease (pinteraction 5
0.078, figure 3). The effect of AIT on stroke was
largest in the first year after diagnosis (RR 5 1.33,
95% CI: 1.14–1.56) and was increased both in the
first 6 months (RR5 1.44, 95% CI: 1.17–1.78) and
7 to 12 months after start of treatment (RR 5 1.22,
95% CI: 1.02–1.55). Subsequent RRs were stable
with all 95% CIs including 1.0. Similar results were
obtained for analyses using TIA or stroke and TIA
alone as the outcome. There was no evidence that the
effect of AIT varied with age (pinteraction 5 0.516).
All sensitivity analyses showed results compatible
to those obtained from the main analyses (data not
shown).
DISCUSSION Our study provides strong evidence
for a slightly increased risk of stroke in patients with
AIT, particularly in the first year after AIT diagnosis.
Our analyses indicated that people with AIT were
more likely to develop hyperlipidemia, CHD, and
CHF, adding evidence to previous discussions about
whether AIT is associated with these factors, and that
some, but not all, of the increased risk of stroke
among patients with AIT was mediated via these clas-
sic cardiovascular risk factors.14
Few previous studies have focused on potential as-
sociations between hypothyroidism or AIT and
stroke. Our systematic review identified 7 studies,
which showed effect sizes ranging from 0.8 to 1.6
(table e-2). All of these studies except for the Scottish
study from 2006 were small and had effect estimates
with wide CIs that overlapped with those from the
present study. Other methodologic limitations of pre-
vious studies included overadjustment for variables
that could be mediators of increased stroke risk, and
residual confounding (for example, the Scottish study
Figure 2 Hypothesized interrelationships among AIT, stroke, and other variables
(A) Conceptual framework for association between AIT and stroke. (B) Differentiation between confounding and mediating
effects of factors hypothesized to be on the causal pathway. Presence of factors at the index date was assumed to be
attributable to confounding in the primary analysis. AIT5 autoimmune thyroiditis; BMI5 body mass index; CHD5 coronary
heart disease; CHF 5 congestive heart failure.
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Table 1 Baseline characteristics of individuals with and without AIT
AIT (n 5 34,907), median (IQR) No AIT (n 5 149,632), median (IQR) p Valuea
Age at entry, y 59.8 (47.2–72.7) 57.0 (44.0–70.6) ,0.001
Years of follow-up 3.3 (1.6–6.1) 2.9 (1.4–5.3) ,0.001
AIT (n 5 34,907) No AIT (n 5 149,632)
No. % No. % p Valuea
Sex ,0.001
Male 6,472 18.5 29,817 19.9
Female 28,435 81.5 119,815 80.1
Hypertension ,0.001
No 23,935 68.6 113,102 75.6
Yes 10,972 31.4 36,530 24.4
Diabetes ,0.001
No 32,713 93.7 143,129 95.6
Yes 2,194 6.3 6,503 4.4
CHD ,0.001
No 31,024 88.9 139,062 92.9
Yes 3,883 11.1 10,570 7.1
AF ,0.001
No 33,444 95.8 146,572 98.0
Yes 1,463 4.2 3,060 2.0
CHF ,0.001
No 33,532 96.2 146,442 97.9
Yes 1,375 3.8 3,190 2.1
Hyperlipidemia ,0.001
No 30,002 86.0 135,794 90.8
Yes 4,905 14.0 13,838 9.2
Smoking status ,0.001
Non 12,869 36.9 55,441 37.1
Ex 10,590 30.3 36,393 24.3
Current 10,377 29.7 49,886 33.3
Unknown 1,071 3.1 7,912 5.3
Alcohol consumption ,0.001
None 6,901 19.8 25,236 16.9
Ex 466 1.3 1,503 1.0
Rare 21,782 62.4 90,814 60.6
Moderate 1,653 4.7 9,450 6.3
Heavy 156 0.5 994 0.7
Unknown 3,949 11.3 21,635 14.5
BMI, kg/m2 ,0.001
<20 1,352 3.9 8,523 5.7
20–24.9 9,152 26.2 49,231 32.9
25–30 10,985 31.5 43,093 28.8
>30 9,166 26.3 25,760 17.2
Unknown 4,252 12.2 23,025 15.4
Continued
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lacked information on smoking, alcohol use, and
medication history).7,12,22–26 Also, studies included in-
dividuals with a history of stroke. This could explain
their slightly higher effect estimates, because thyroid
hormone status is often assessed at stroke units, re-
sulting in better AIT ascertainment in individuals
with a stroke history (who are at higher risk of a
subsequent stroke). Three of the studies were concep-
tually different from this study because they used
asymptomatic patients identified as hypothyroid by
laboratory tests who were mostly untreated with
thyroxine.7,12,25
We found differences between individuals with
and without AIT in the prevalence of traditional car-
diovascular risk factors at baseline. Individuals with
AIT were more likely to have AF and hypertension
at baseline compared to those without AIT; however,
they were not at increased risk of developing these
conditions during follow-up. This finding is consis-
tent with that from a recent population-based study
from Germany, which reported that hypothyroidism
was associated with prevalent but not incident hyper-
tension.33 Hypertension and AF may not be on the
causal pathway between AIT and stroke, although the
differences we observed at baseline could represent
early changes induced by undiagnosed AIT. Differen-
ces in AF (and possibly hypertension) at baseline
between individuals with AIT and those without could
also be explained by differences in ascertainment of
AIT, if individuals with AF were more likely to have
thyroid-stimulating hormone levels measured.
Our main model of interest, adjusted for these
baseline variables, is based on the assumption that
pathologic mechanisms on the causal pathway to
stroke did not start until after AIT diagnosis and ini-
tiation of thyroxine treatment. Thus, these factors
were treated as potential confounders. However, it
is likely that the date of AIT diagnosis/start of treat-
ment did not accurately capture start of disease.
Given that patients with AIT often present with non-
specific symptoms, diagnosis of AIT can be delayed.
Thus, it is plausible that cardiovascular causal pro-
cesses could have started before formal diagnosis of
AIT. If so, model 3 (which adjusted for these varia-
bles) may have provided a conservative estimate of rel-
ative stroke risk, and model 2 might provide an
estimate closer to the true effect. However, the effect
estimates produced by these 2 models were similar;
also, the sensitivity analysis excluding all individuals
with cardiovascular disease–related conditions at
baseline showed results similar to the main analysis.
Our finding of a higher effect of AIT on stroke risk
in the first year after diagnosis is compatible with the
hypothesis of increased cerebrovascular risk in pa-
tients with AIT due to prediagnosis hypothyroidism
and the time taken to reduce this risk after thyroid
hormone replacement. There was no evidence for
an increasing effect with increased length of follow-
up (a possible proxy for a long-term effect mediated
by autoimmune processes). An alternative explana-
tion is that the observed effect of AIT on stroke was
caused by thyroxine treatment because thyroxine
can have a procoagulant effect.34 However, if the
observed effect was due to thyroxine, we might expect
to have seen the excess stroke risk restricted to the
period soon after start of treatment, whereas the risk
remained increased 6 to 12 months after diagnosis in
our study. Moreover, a thyroxine-mediated effect
might also be expected to generate short-term differ-
ences in incidence of AF between patients with AIT
and individuals without AIT because thyroxine in high
doses can induce AF; this was not the case. Neverthe-
less, we cannot exclude that some of the effect attrib-
uted to hypothyroidism could have been due to
thyroxine, and we were unable to examine this for-
mally because all patients with AIT received thyroxine.
This study has several strengths. We used a con-
siderably larger study population than all previous
studies, and thus had greater power to ascertain effect
estimates. We had information on a variety of poten-
tial confounding factors that could be considered in
the analysis. Unlike previous studies, we excluded
Table 1 Continued
AIT (n 5 34,907) No AIT (n 5 149,632)
No. % No. % p Valuea
Consultation rateb ,0.001
1st quartile 506 1.5 44,074 30.9
2nd quartile 5,817 17.3 37,481 26.3
3rd quartile 12,218 36.3 31,481 22.1
4th quartile 15,102 44.9 29,759 20.8
Abbreviations: AF 5 atrial fibrillation; AIT 5 autoimmune thyroiditis; BMI 5 body mass index; CHD 5 coronary heart
disease; CHF 5 congestive heart failure; IQR 5 interquartile range.
aCalculated using x2 tests and Wilcoxon rank-sum tests as appropriate.
b People with less than 3 months of follow-up were excluded (1,260 [3.6%] exposed, 6,837 [4.6%] unexposed).
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individuals with a history of stroke, avoiding intro-
duction of bias. Moreover, excluding people with
other autoimmune diseases from our study popula-
tion enabled us to observe the effect of AIT unmod-
ified by other autoimmune disorders. This might not
have been the case in other studies, because patients
with AIT are at higher risk of acquiring other autoim-
mune disorders, some of which (e.g., rheumatoid
arthritis, type 1 diabetes) are associated with consider-
ably increased risk of cardio- and cerebrovascular
disease.16,35
Potential limitations of our study also need con-
sideration. Almost all noniatrogenic hypothyroidism
in the United Kingdom is due to AIT, and we
excluded individuals who had other reasons for hypo-
thyroidism. However, our Read code list included
nonspecific hypothyroidism codes, which increased
sensitivity of AIT diagnosis but could have included
a few non-AIT cases. Because hypothyroidism can
remain undiagnosed for an unspecified time, some
patients with AIT could have been misclassified as
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Figure 3 Effect of autoimmune thyroiditis on
stroke stratified by time since
diagnosis (first thyroxine script)
*Adjusted for current age, sex, alcohol, smoking, hyperten-
sion, atrial fibrillation, hyperlipidemia, and body mass index
(all at baseline) and allowing for clustering in practice.
**Using a likelihood ratio test to compare a model with
against a model without an interaction term for time since
diagnosis. CI 5 confidence interval; RR 5 rate ratio.
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unexposed. This is likely to have happened largely
independently of subsequent stroke risk, and thus
may have driven the RR toward 1.0. Those with pre-
existing AF could have been more likely to have their
AIT diagnosed, which could have resulted in some
overestimation of the effect size of AIT on the risk
of stroke. However, our sensitivity analyses excluding
individuals with AF at baseline indicate that this is
unlikely to have been a major problem.
Differential misclassification of the outcome was
unlikely in this study because stroke is a serious con-
dition and should have been recorded equally in both
groups independent of AIT status, or health-seeking
behavior. However, we could not differentiate
between cases of ischemic and hemorrhagic stroke,
because 85% of stroke codes did not specify the
stroke subtype, consistent with previous studies of
stroke using electronic health data.23,36 We hypothe-
sized that AIT might be associated specifically with
ischemic stroke because hypothyroidism is linked
with classic risk factors for ischemia.3,15–18,20,21,37
Moreover, carotid artery intima-media thickness
and AF, 2 large risk factors for ischemic stroke, have
been linked to AIT.22,23,27 Ischemic stroke causes
approximately 80% of stroke cases in adults, and
effect sizes for TIA (an ischemic process) were com-
parable to those shown for stroke in our study, further
supporting that AIT is associated with ischemic
stroke. Nevertheless, AIT could also affect the risk
of hemorrhagic stroke, because hypothyroidism has
been shown to be associated with the development of
von Willebrand syndrome and bleeding events.38
Individuals with AIT had higher consultation rates
than those without AIT. It is therefore possible that
they were more likely to be diagnosed and treated
for conditions such as hyperlipidemia or hyperten-
sion. Monitoring and prompt treatment of these con-
ditions could have decreased stroke risk associated
with these conditions and might partly explain the
relatively small increase in stroke risk associated with
AIT. Nevertheless, this study provides a realistic pic-
ture of the residual effect of AIT after standard treat-
ment and surveillance in the United Kingdom. Data
concerning the potential confounders of ethnicity and
socioeconomic status were not available. However,
socioeconomic status was partly accounted for by
allowing for clustering by practice.
Although THIN has been shown to be representa-
tive for the UK population, the results of this study
might not be generalizable to all patients with AIT.
We included only patients with AIT who received
thyroxine treatment. This excluded patients who
had never had hypothyroidism. If hypothyroidism is
on the causal pathway between AIT and stroke, the
observed effect relates to treated rather than all pa-
tients with AIT. Excluding individuals with AIT
who had a second autoimmune disorder allowed us
to pinpoint the specific effect of AIT, but may have
excluded some patients with AIT who had stronger
autoimmune processes and thus might not have cap-
tured all of the long-term risk of stroke mediated by
autoimmune pathology.
Our study has demonstrated a 10% to 14%
increased risk of stroke among patients with hypothy-
roid AIT after extensive consideration of confounding
and potential biases. Given the relatively high preva-
lence of AIT and the morbidity and mortality associ-
ated with stroke, even small increases in stroke risk
might be of high clinical relevance. The results of
our study highlight the potential for regular screening
for cardiovascular risk factors and preventive treat-
ment (e.g., with statins) in patients with AIT.
Comment:
Does L-thyroxine prevent or cause stroke in hypothyroidism?
The association between overt hypothyroidism and atherosclerotic risk fac-
tors, especially hypertension and dyslipidemia, is clear. To date, only a few small
and methodologically flawed epidemiologic studies have investigated the relation-
ship between hypothyroidism and stroke, precluding definitive conclusions. In the
current issue of Neurology®, Karch and Thomas1 present a large well-designed
case-control study investigating this relationship. They compared 34,907 patients
with autoimmune thyroiditis on treatment with L-thyroxine and 149,632 matched
individuals without autoimmune thyroiditis from a UK primary care electronic
health record system. They found a slight increase in the risk of stroke in patients
with autoimmune thyroiditis (adjusted relative risk5 1.10, 95% confidence inter-
val: 1.01–1.20) compared with controls. Some of this increased risk of stroke was
independent of cardiovascular risk factors.
Overall, these data suggest that thyroid hormone deficiency may cause stroke
independent of atherosclerosis and hypertension. This raises the question of the
mechanism of the observed association. Some patients with overt hypothyroidism
and bleeding complications have an acquired von Willebrand syndrome, suggest-
ing an effect of thyroid hormones on von Willebrand factor synthesis.2 This study
defined stroke as ischemic or hemorrhagic, therefore some of the difference may be
explained by more bleeding events. Alternatively, L-thyroxine treatment and not
low thyroid hormones per se could explain the increased risk. L-Thyroxine
increases coagulation factor levels, in particular von Willebrand factor and factor
VIII, and inhibits fibrinolysis in a dose-dependent manner.3 This may lead to a
temporarily increased ischemic stroke risk in patients with autoimmune thyroiditis
who have a higher prevalence of obesity, hypertension, diabetes, and atrial fibril-
lation.1 This theory is supported by the observation of higher risk during the first
year after diagnosis (relative risk 5 1.33, 95% confidence interval: 1.14–1.56)
compared with long-term follow-up.
Future epidemiologic studies should investigate stroke risk not only after but
also before L-thyroxine start and should discriminate between ischemic and hem-
orrhagic stroke.
1. Karch A, Thomas SL. Autoimmune thyroiditis as a risk factor for stroke: a historical
cohort study. Neurology 2014;82:1643–1652.
2. Stuijver DJ, Piantanida E, van Zaane B, et al. Acquired von Willebrand syndrome in
patients with overt hypothyroidism: a prospective cohort study. Haemophilia Epub
2013 Oct 14.
3. Van Zaane B, Squizzato A, Debeij J, et al. Alterations in coagulation and fibrinolysis
after levothyroxine exposure in healthy volunteers: a controlled randomized crossover
study. J Thromb Haemost 2011;9:1816–1824.
Alessandro Squizzato, MD, PhD
Victor E.A. Gerdes, MD, PhD
From the Research Center on Thromboembolic Disorders and Antithrombotic Therapies (A.S.), Department of
Clinical Medicine, University of Insubria, Varese, Italy; and Department of Internal Medicine (V.E.A.G.),
Slotervaart Hospital, Amsterdam, the Netherlands.
Study funding: No targeted funding reported.
Disclosure: The authors report no disclosures. Go to Neurology.org for full disclosures.
1650 Neurology 82 May 6, 2014
AUTHOR CONTRIBUTIONS
S.T. conceived the study. Both authors developed the study design. A.K.
conducted the data management, analyzed the data, and wrote the man-
uscript, with contributions from S.T. Both authors interpreted the find-
ings, contributed to critical revision of the manuscript for important
intellectual content, and approved the final version.
ACKNOWLEDGMENT
The authors thank Ian Douglas for providing the original medical and
therapy code lists for various cofactors.
STUDY FUNDING
Supported by a project grant from the Wellcome Trust (079482/Z/06/Z)
and by a postgraduate fellowship of the DAAD (German Academic
Exchange Service, for A.K.).
DISCLOSURE
The authors report no disclosures relevant to the manuscript. Go to
Neurology.org for full disclosures.
Received June 25, 2013. Accepted in final form January 16, 2014.
REFERENCES
1. Flynn RW, MacDonald TM, Morris AD, Jung RT,
Leese GP. The thyroid epidemiology, audit, and research
study: thyroid dysfunction in the general population.
J Clin Endocrinol Metab 2004;89:3879–3884.
2. McGrogan A, Seaman HE, Wright JW, de Vries CS.
The incidence of autoimmune thyroid disease: a systematic
review of the literature. Clin Endocrinol 2008;69:
687–696.
3. Roberts CG, Ladenson PW. Hypothyroidism. Lancet
2004;363:793–803.
4. Weetman A. Thyroid disease. In: Rose N, Mackay I, edi-
tors. The Autoimmune Diseases. San Diego: Academic
Press; 2006.
5. Aho K, Gordin A, Palosuo T, et al. Thyroid autoimmunity
and cardiovascular diseases. Eur Heart J 1984;5:43–46.
6. Bauer DC, Rodondi N, Stone KL, Hillier TA. Thyroid
hormone use, hyperthyroidism and mortality in older
women. Am J Med 2007;120:343–349.
7. Cappola AR, Fried LP, Arnold AM, et al. Thyroid status,
cardiovascular risk, and mortality in older adults. JAMA
2006;295:1033–1041.
8. Gussekloo J, van Exel E, de Craen AJ, Meinders AE,
Frolich M, Westendorp RG. Thyroid status, disability
and cognitive function, and survival in old age. JAMA
2004;292:2591–2599.
9. Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A,
Witteman JC. Subclinical hypothyroidism is an indepen-
dent risk factor for atherosclerosis and myocardial infarc-
tion in elderly women: the Rotterdam Study. Ann Intern
Med 2000;132:270–278.
10. Imaizumi M, Akahoshi M, Ichimaru S, et al. Risk for ische-
mic heart disease and all-cause mortality in subclinical hypo-
thyroidism. J Clin Endocrinol Metab 2004;89:3365–3370.
11. Parle JV, Maisonneuve P, Sheppard MC, Boyle P,
Franklyn JA. Prediction of all-cause and cardiovascular mor-
tality in elderly people from one low serum thyrotropin
result: a 10-year cohort study. Lancet 2001;358:861–865.
12. Rodondi N, Newman AB, Vittinghoff E, et al. Subclinical
hypothyroidism and the risk of heart failure, other cardi-
ovascular events, and death. Arch Intern Med 2005;165:
2460–2466.
13. Vanderpump MP, Tunbridge WM, French JM, et al. The
development of ischemic heart disease in relation to auto-
immune thyroid disease in a 20-year follow-up study of an
English community. Thyroid 1996;6:155–160.
14. Ochs N, Auer R, Bauer DC, et al. Meta-analysis: subclinical
thyroid dysfunction and the risk for coronary heart disease
and mortality. Ann Intern Med 2008;148:832–845.
15. Diekman T, Lansberg PJ, Kastelein JJ, Wiersinga WM.
Prevalence and correction of hypothyroidism in a large
cohort of patients referred for dyslipidemia. Arch Intern
Med 1995;155:1490–1495.
16. Frostegard J. Atherosclerosis in patients with autoim-
mune disorders. Arterioscler Thromb Vasc Biol 2005;
25:1776–1785.
17. Morris MS, Bostom AG, Jacques PF, Selhub J,
Rosenberg IH. Hyperhomocysteinemia and hypercholes-
terolemia associated with hypothyroidism in the third
US National Health and Nutrition Examination Survey.
Atherosclerosis 2001;155:195–200.
18. Polikar R, Burger AG, Scherrer U, Nicod P. The thyroid
and the heart. Circulation 1993;87:1435–1441.
19. Saito I, Saruta T. Hypertension in thyroid disorders.
Endocrinol Metab Clin North Am 1994;23:379–386.
20. Shah JH, Motto GS, Papagiannes E, Williams GA. Insulin
metabolism in hypothyroidism. Diabetes 1975;24:922–925.
21. Squizzato A, Gerdes VE, Brandjes DP, Buller HR, Stam J.
Thyroid diseases and cerebrovascular disease. Stroke 2005;
36:2302–2310.
22. Dorr M, Empen K, Robinson DM, Wallaschofski H,
Felix SB, Volzke H. The association of thyroid function
with carotid artery plaque burden and strokes in a
population-based sample from a previously iodine-
deficient area. Eur J Endocrinol 2008;159:145–152.
23. Flynn RW, Macdonald TM, Jung RT, Morris AD,
Leese GP. Mortality and vascular outcomes in patients
treated for thyroid dysfunction. J Clin Endocrinol Metab
2006;91:2159–2164.
24. Karakurum Goksel B, Karatas M, Nebioglu A, et al. Sub-
clinical hypothyroidism, hyperhomocysteinemia and dysli-
pidemia: investigating links with ischemic stroke in
Turkish patients. Neurol Res 2007;29:871–876.
25. Qureshi AI, Suri FK, Nasar A, Kirmani JF, Divani AA,
Giles WH. Free thyroxine index and risk of stroke: results
from the National Health and Nutrition Examination Survey
Follow-up Study. Med Sci Monit 2006;12:CR501–CR506.
26. Remmel KS, Wanahita A, Moore K, Gruenthal M. Acute
ischemic stroke and hypothyroidism. J Ky Med Assoc
2006;104:191–193.
27. Ciccone MM, De Pergola G, Porcelli MT, et al. Increased
carotid IMT in overweight and obese women affected by
Hashimoto’s thyroiditis: an adiposity and autoimmune
linkage? BMC Cardiovasc Disord 2010;10:22.
28. Roifman I, Beck PL, Anderson TJ, Eisenberg MJ, Genest J.
Chronic inflammatory diseases and cardiovascular risk: a
systematic review. Can J Cardiol 2011;27:174–182.
29. The Health Improvement Network. The Health Improvement
Network [online]. Available at: http://www.thin-uk.com/.
Accessed June 8, 2011.
30. Lewis JD, Schinnar R, Bilker WB, Wang X, Strom BL.
Validation studies of The Health Improvement Network
(THIN) database for pharmacoepidemiology research.
Pharmacoepidemiol Drug Saf 2007;16:393–401.
31. Ruigomez A, Martin-Merino E, Rodriguez LA. Validation
of ischemic cerebrovascular diagnoses in The Health
Neurology 82 May 6, 2014 1651
Improvement Network (THIN). Pharmacoepidemiol
Drug Saf 2010;19:579–585.
32. Sjolander A, Greenland S. Ignoring the matching variables
in cohort studies: when is it valid and why? Stat Med
2013;32:4696–4708.
33. Ittermann T, Tiller D, Meisinger C, et al. High serum
TSH levels are associated with current but not with inci-
dent hypertension. Thyroid 2013;23:955–963.
34. Van Zaane B, Squizzato A, Debeij J, et al. Alterations in
coagulation and fibrinolysis after levothyroxine exposure in
healthy volunteers: a controlled randomized crossover
study. J Thromb Haemost 2011;9:1816–1824.
35. Somers EC, Thomas SL, Smeeth L, Hall AJ. Autoim-
mune diseases co-occurring within individuals and
within families: a systematic review. Epidemiology
2006;17:202–217.
36. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P,
Vallance P. Risk of myocardial infarction and stroke after
acute infection or vaccination. N Engl J Med 2004;351:
2611–2618.
37. Saito T, Masuda Y, Ozawa T, Endo M, Murayama H.
Proceedings: changes in renin-angiotensin system in essen-
tial hypertension and thyroid diseases [in Japanese]. Nihon
Naibunpi Gakkai Zasshi 1974;50:438.
38. Manfredi E, van Zaane B, Gerdes VE, Brandjes DP,
Squizzato A. Hypothyroidism and acquired von Wille-
brand’s syndrome: a systematic review. Hemophilia 2008;
14:423–433.
Earn 20 CME Credits Toward MOC with New
NeuroPISM Modules
Choose from the latest lineup of quality modules to join the AAN’s exclusive performance improve-
ment programs designed to help you address both the Performance in Practice (PIP) and Continu-
ing Medical Education (CME) components of Maintenance of Certification (MOC).
• NEW! Distal Symmetric Polyneuropathy (DSP) includes eight quality measures, addressing
accurate and appropriate evaluation/monitoring of DSP and associated symptoms to guide treat-
ment options, patient safety, and best practices to assist patients in managing their pain and
improving quality of life
• Acute Stroke addresses six quality measures, including deep vein thrombosis prophylaxis
(DVT) for ischemic stroke or intracranial hemorrhage, discharged on antiplatelet therapy, dys-
phagia screening, rehabilitation service considerations, and more
• Dementia includes 10 quality measures addressing underuse of effective services and patient-
centered care strategies, and patient safety issues
Learn about all of the other available modules and purchase yours today:
www.aan.com/view/neuropi
Call for Submissions: Global Perspectives!
Section Co-Editors Johan A. Aarli, MD, and Oded Abramsky, MD, PhD, FRCP, encourage sub-
missions to the Global Perspectives section that provides a platform in Neurology for news about
scientific findings or academic issues. News may include international research content, spotlights
on specific neurologic practice concerns within a country, or important information about interna-
tional educational or scientific collaborative efforts.
Submissions must be 1,250 words or less with five or less references. A maximum of two figures or
two tables (or combination) can be incorporated if necessary. For complete submission require-
ments, please go to www.neurology.org and click on “Information for Authors.” The submissions
will be reviewed by the editors and may be edited for clarity.
Interested submitters can register and upload manuscripts under the section “Global Perspectives”
at http://submit.neurology.org. Please send inquiries to Kathy Pieper, Managing Editor, Neurology;
kpieper@neurology.org.
1652 Neurology 82 May 6, 2014
